Recent work using expression profiling to computationally predict the estrogen receptor (ER) status of breast tumors has revealed that certain tumors are characterized by a high prediction uncertainty ('low-confidence'). We analyzed these 'low-confidence' tumors and determined that their 'uncertain' prediction status arises as a result of widespread perturbations in multiple genes whose expression is important for ER subtype discrimination. Patients with 'low-confidence' ERþ tumors exhibited a significantly worse overall survival (P ¼ 0.03) and shorter time to distant metastasis (P ¼ 0.004) compared with their 'high-confidence' ERþ counterparts, indicating that the 'high-' and 'low-confidence' binary distinction is clinically meaningful. We then discovered that elevated expression of the ERBB2 receptor is significantly correlated with a breast tumor exhibiting a 'low-confidence' prediction, and this association was subsequently validated across multiple independently derived breast cancer expression datasets employing a variety of different array technologies and patient populations. Although ERBB2 signaling has been proposed to inhibit the transcriptional activity of ER, a large proportion of the perturbed genes in the 'low-confidence'/ERBB2þ samples are not known to be estrogen responsive, and a recently described bioinformatic algorithm (DEREF) was used to demonstrate the absence of potential estrogenresponse elements (EREs) in their promoters. We propose that a significant portion of ERBB2's effects on ERþ breast tumors may involve ER-independent mechanisms of gene activation, which may contribute to the clinically aggressive behavior of the 'low-confidence' breast tumor subtype.
INTRODUCTION
The classification of breast tumors into estrogen receptor positive (ERþ) and negative (ERÀ) subtypes is a critical distinction in the treatment of breast cancer. ERÀ tumors are in general more clinically aggressive than their ERþ counterparts, and ERþ tumors are routinely treated using anti-hormonal therapies such as tamoxifen (1) . Presently, a tumor's ER status is routinely determined by immunohistochemistry (IHC) or immunoblotting using an antibody to ER. This technique, however, is imperfect-for example, it may fail to detect tumors harboring genetic alterations in ER that render it inactive or constitutively active (2) . Thus, it is crucially important to develop more accurate methodologies to improve the ER subtype classification of breast tumors, so that the appropriate therapies can be subsequently applied.
A number of groups have recently published reports utilizing expression profile data to classify breast cancers into ERþ and ERÀ categories. In one study, it was found that the expression profiles of ERþ and ERÀ tumors are 'remarkably distinct', supporting previous theories that ERþ and ERÀ tumors may arise from distinct breast epithelial cell types (3) . Another group has reported the use of supervised learning methodologies on expression data to classify breast tumors by ER subtype (4) . One common observation in these studies was that, although the majority of breast tumors could usually be accurately classified into ERþ and ERÀ subtypes to a high degree of certainty, there always existed a set of 'lowconfidence' samples that were either misclassified or where the statistical confidence of the predictions was marginal. Although it was proposed that these 'low-confidence' samples might reflect the effects of population heterogeneity (4), the hypothesis that such 'low-confidence' samples might be biologically distinct from their 'high-confidence' counterparts has not been fully explored to date.
The experiments in this report were motivated by the possibility that the 'low-confidence' samples might possess distinct biological characteristics. We performed a classification analysis using an in-house generated breast cancer expression dataset, and determined that, in comparison to the 'high confidence' tumors, the 'low-confidence' tumors exhibited widespread perturbations in the expression of multiple genes important for ER subtype discrimination. Although initially derived through purely computational means, the distinction between 'high-' and 'low-confidence' tumors is clinically meaningful, as 'low-confidence' ERþ tumors exhibited a significantly worse overall survival and shorter time to distant metastasis than their 'high-confidence' ERþ counterparts. Such a distinction is currently not discernible by conventional immunohistochemical strategies used to detect ER. We then unexpectedly discovered that high expression levels of the ERBB2 receptor are significantly correlated with breast tumors exhibiting a 'low-confidence' prediction, and validated this association across three independently derived breast cancer expression datasets generated from different patient populations/array technologies, and analyzed using different computational methods. The association between ERBB2 expression and the widespread perturbations of ER-discriminator genes observed in the 'low-confidence' tumors is intriguing, as ERBB2 activity is known to contribute, in both breast tumors and cell lines, towards the development of resistance to antihormonal therapies (5, 6) , and to inhibit the transcriptional activity of ER (5,7). However, despite being important for ER subtype discrimination, we found that a significant proportion of these 'perturbed' genes, are not known to be estrogen responsive and, using a recently described bioinformatic algorithm (DEREF), also demonstrated that these genes do not contain potential estrogen-response elements (EREs) in their promoters. Our results suggest that, in addition to current models where ERBB2 acts primarily by disrupting the transcriptional activity of ER, a significant fraction of ERBB2's effects on ERþ breast tumors may involve ERindependent mechanisms of gene activation as well, which may collectively contribute to the clinically aggressive nature of the 'low-confidence' breast tumor subtype.
RESULTS
Classification of breast tumors by ER status using expression profiles from Chinese patients reveals a distinct population of 'low-confidence' samples
The overall incidence patterns of breast cancer in Caucasian and Asian populations are distinct (8) , prompting us to investigate if findings from previous reports (3, 4) could also be observed in our local patient population. We first used gene expression profile data to classify a set of breast tumors by their ER status. A training set of 55 breast tumors was selected, where the ER status of each tumor was pre-determined using IHC. Two classification methods were tested: weighted-voting (WV) and support vector machines (SVM), and classification accuracy was assessed through leave-one-out cross-validation (LOOCV; Supplementary Material). In addition to classifying a sample, quantitative metrics were used to provide an assessment of classification uncertainty (Materials and Methods). For this and all subsequent analyses (including independent data sets), similar results were obtained when the cutoff threshold defining a 'high' versus 'low' confidence sample was varied by AE 10% (Supplementary Material). The overall classification accuracy on the training set was 95% (WV) and 96% (SVM), with seven samples characterized by 'low-confidence' or marginal predictions (gray box, Fig. 1A ). To determine if such 'low-confidence' samples could also be observed in an independent set of tumors, a second set of 41 tumors was used as an independent test set. Although the overall classification accuracy on the independent test set was 91% (WV and SVM), nine samples once again displayed a 'lowconfidence' prediction (Fig. 1B) . Thus, using two different classification methods (WV and SVM), certain breast tumors were found to exhibit a distinct 'low-confidence' character when being classified by ER status on the basis of their gene expression profiles.
Patients with 'low-confidence' ERþ tumors exhibit decreased overall survival and shorter time to distant metastasis in comparison to patients with 'high-confidence' ERþ tumors Since the differentiation of tumors into 'high-' and 'lowconfidence' sub-populations was achieved through a purely computational analysis of tumor gene expression profiles, it is unclear if this distinction is biologically or clinically meaningful, and if the use of gene expression profiles in this manner affords any substantial advantage over conventional immunohistochemical techniques to determine the ER status of breast tumors. To address this issue, we investigated if the 'lowconfidence' tumors might exhibit any clinical behaviors distinct from their 'high-confidence' counterparts. We used two publicly available breast cancer expression data sets for which related but distinct types of clinical information was available. The first set (9) consists of a cDNA microarray data set of 78 breast carcinomas and seven non-malignant samples with overall patient survival information (referred to as the Stanford data set). The second set (10) consists of 71 ERþ and 46 ERÀ lymph-node negative tumors profiled using oligonucleotidebased microarrays, and for 97 tumors the time interval from initial tumor diagnosis to the appearance of a new distant metastasis was available (referred to as the Rosetta data set). We used WV to classify the breast tumors in the Stanford and Rosetta datasets by their ER subtype (Supplementary Material). Consistent with our own data set, among the 56 ERþ and 18 ERÀ tumors in the Stanford data set (four tumors were removed due to lack of ER status or other clinical information), we observed an overall LOOCV accuracy of 93%, with 14 tumors (18.9%) being classified as 'low-confidence'. Similarly, the WV analysis also identified 18 out of 117 tumors (15.4%) in the Rosetta data set as exhibiting a 'low-confidence' classification, with an overall LOOCV accuracy of 92%. These figures are comparable to that observed in our own patient population, suggesting that 'low-confidence' tumors occupy between 15 and 19% of the overall breast tumor population.
We then compared the clinical behaviour of the 'high-' and 'low-confidence' tumor populations using Kaplan-Meier analysis. As shown in Figure 2 , patients with 'low-confidence' tumors exhibited a significantly worse overall survival (P ¼ 0.0003, log-rank test) and shorter time to distant metastasis (P ¼ 0.0001, log-rank test) than their 'high-confidence' counterparts. This result indicates that the 'high' versus 'lowconfidence' binary distinction is indeed clinically meaningful. We then repeated this analysis under conditions where the tumors were first subdivided into independent ERþ and ERÀ categories. For ERþ tumors, we once again found that 'lowconfidence' ERþ tumors were associated with a significantly worse overall survival (P ¼ 0.03, log-rank test) and shorter time to metastasis (P ¼ 0.004, log-rank test; Fig. 2 ) than 'high-confidence' ERþ tumors. No statistically significant differences in overall survival and time to metastasis were observed for the ERÀ tumors (P. Tan, unpublished data). These results indicate that ERþ tumors can be subdivided on the basis of the 'high-' and 'low-confidence' binary classification into distinct disease groups exhibiting different clinical behaviors. Since distinguishing between these two groups is currently not possible by conventional immunohistochemical methods used for ER detection, this result also demonstrates how gene expression profile data can be a useful adjunct to conventional strategies for breast cancer prognostication and staging. 'Low-confidence' tumors exhibit widespread perturbations in the expression of genes important for ER subtype discrimination
The classification algorithms used in these and other studies (e.g. WV, SVM, ANN, see below) all rely upon the combinatorial input of multiple discriminator genes whose individual contributions are then combined to arrive at a particular classification decision (i.e. if the tumor is ERþ or ERÀ). It is formally possible that the 'low-confidence' prediction status of these breast tumors is due to either the dramatic deregulation of a few key discriminator elements (i.e. specific effects), or the more subtle perturbation of a large number of discriminator genes (i.e. widespread effects). To distinguish between these two possibilities, we compared the expression levels of genes important for ER subtype discrimination between 'high-' and 'low-confidence' tumors. First, to identify ER-discriminating genes which where differentially regulated between ERþ and ERÀ tumors, we utilized a statistical technique called significance analysis of microarrays (SAM) (11) . Employing our combined dataset (total number ¼ 96 tumors), a total of 133 differentially regulated genes (SAM-133) were identified at a 'false discovery rate' (FDR) of 0% (the FDR is an index used by SAM to estimate the number of false positives-an FDR of 10% for 100 genes indicates that 10 genes are likely to be false positives). In this set, 122 genes were up-regulated in ERþ samples (i.e. positively correlated to ER status), while the remaining 11 were down-regulated in ERþ tumors (i.e. negatively correlated to ER). As predicted, the SAM-133 gene set includes a number of genes related to the ER pathway, such as ESR1, LIV1 (an estrogen-inducible gene) and TFF1, and some genes (e.g. GATA-3) were identified multiple times. A number of genes in the SAM-133 list are also found in similar lists reported by others (3, 4) .
We then subdivided the ERþ and ERÀ tumors each into 'high-' and 'low-confidence' categories (i.e. ERþ/High, ERþ/ Low, ERÀ/High, ERÀ/Low), and the expression levels of the SAM-133 genes were compared between the groups (Fig. 3) . Of the 122 genes in the SAM-133 gene set that were positively correlated to ER status, $62% exhibited a significantly lower average expression level (referred as 'perturbed expression') in the ERþ/Low samples compared to the ERþ/High tumors (P < 0.05, Fig. 3A and Table 2 ). Genes with 'perturbed' expression included ER, GATA3, BCL2, IGF1R and RARA, while other ER-discriminator genes, such as TFF1, TFF3 and XBP1, were unaffected. Similarly, in the ERÀ 'high-' and 'lowconfidence' samples, we witnessed a reciprocal pattern where $42% of the 122 genes exhibited a higher average expression level in the ERÀ/Low samples compared with the ERÀ/High tumors (P < 0.05, Fig. 3B and Table 2 ). Intriguingly, although the expression levels of certain genes (e.g. GATA3, BCL2) were commonly perturbed between 'low-' and 'highconfidence' samples in both the ERþ and ERÀ subtypes, the perturbation of other genes appeared to be subtype-specific. For example, ESR1 and IGFR1 were only perturbed in the ERþ samples, while XBP1 was only perturbed in the ERÀ samples. Finally, there were minimal changes in the expression levels of ER-discriminating genes that were negatively correlated to ERþ status (i.e. highly expressed in ERÀ tumors; Fig. 3C and D) . This result suggests that the expression perturbations observed in the 'low-confidence' samples, although widespread, are primarily observed in genes whose expression is positively correlated to ER (Supplementary Material).
Elevated expression of the ERBB2 oncogene is significantly associated with the 'low-confidence' predictions
The expression perturbations observed in the 'low-confidence' breast tumors could be due to multiple reasons, ranging from experimental variation (e.g. poor sample quality, tumor excision and handling), choice of the classification method, to population and sample heterogeneity. To gain insights into the possible mechanisms underlying these expression perturbations, we attempted to determine if there were any specific histopathological parameters that might be correlated to the 'low-confidence' state. No significant associations were observed between the 'low-confidence' status of a tumor and patient age, lymph node status, tumor grade, p53 mutation status or progesterone receptor status (Table 1) . We discovered, however, a significant positive association (P < 0.001, Supplementary Material) between a tumor's ERBB2 status and a 'low-confidence' prediction. This correlation, observed using the training set data, was then assessed using the independent test set samples. Of the nine 'low-confidence' samples in the independent test set, eight tumors were also ERBB2þ (8/9), indicating that this association is not datasetspecific. Supporting the association between 'low-confidence' status and ERBB2 expression, a principal components analysis (PCA) of the 96 tumors on the basis of the SAM-133 genes effectively subdivided the 'high' confidence ERþ and ERÀ tumors, with the ERBB2þ samples falling in an intermediate 'low-confidence' area (Fig. 3E) .
We also investigated if the correlation between 'lowconfidence' prediction strength and high ERBB2 expression could have been discovered independently by comparing the global expression profiles of 'high-' and 'low-confidence' tumors. First, we compared the 'high-confidence' and 'low-confidence' tumors belonging to the ERþ subtype. A total of 89 genes were identified as being significantly regulated (FDR ¼ 14%). Among the top 50 most significantly up-regulated genes in the ERþ 'low-confidence' samples, three genes-PMNT (ranked fourth), GRB7V (eighth), and ERBB2 (36th) were of particular interest (Supplementary Material), as they are all physically located on the 17q21 region, a frequent target of DNA amplification in breast cancer (12) . In a separate analysis, the ERÀ 'high-confidence' and ERÀ 'low-confidence' samples were also compared. Among the top 50 genes identified as being differentially regulated (FDR ¼ 4%), we once again identified the 17q21 genes PMNT (ranked fifth), GRB7V (10th) and ERBB2 (28th), and a fourth 17q21 gene (hypothetical gene MGC9753), as exhibiting increased expression in the 'low-confidence' samples (Supplementary Material). Indeed, the 17q21 locus was the most commonly identified genomic location for genes exhibiting increased expression in the 'low-confidence' ERþ and ERÀ samples, being represented at almost twice the frequency as compared with the next most common locus (1q21). A permutation analysis utilizing 10 000 randomly generated 50-member gene sets also revealed that the probability at which the same three 17q21 loci might have been selected by chance in two 50-member gene sets was approximately 4.4 Â 10
À10
, suggesting that the identification of the 17q21 locus in the SAM-lists for both ERþ and ERÀ subtypes is significant (Supplementary Material). Taken collectively, these results suggest that for both the ERþ and ERÀ subtypes, the 'low-confidence' breast tumors are significantly associated with increased expression of ERBB2 in comparison with the 'high confidence' tumors, most likely resulting from DNA amplification of the 17q21 locus. We note, however, that the association between 'low-confidence' prediction and ERBB2þ expression, although highly significant, is not perfect, as a few tumors that were designated as ERBB2þ by conventional IHC exhibited 'high-confidence' predictions, while not all 'lowconfidence' tumors are ERBB2þ. One possibility may be that other genes, besides ERBB2, may also contribute to a breast tumor exhibiting a 'low-confidence' state. To validate our finding, we then analyzed the other independently derived breast cancer expression datasets. First, of the nine ERBB2þ tumors in the Stanford data set, all nine were predicted as being in the 'low-confidence' group (P < 0.001, Table 1 and Supplementary Material). Second, in the Rosetta data set, we once again found a significant association between the confidence level of prediction and ERBB2 expression (P < 0.001, Table 1 Figure 4B , depicts the output of the ANN model with sample standard deviations (SD), as assessed using the top 100 discriminator genes for ER subtype. Samples with a wide SD are analogous to the 'low-confidence' status of the WV and SVM methodologies. As can be seen from Figure  4B , ERBB2þ samples (determined in Fig. 4A ) tend to be associated with large SDs, which indicate high uncertainty, particularly for ERþ tumors. Taken collectively, the association between the confidence level of ER prediction and ERBB2 status was observed on a wide range of data sets originating from different laboratories utilizing different microarray technologies (Affymetrix, cDNA and oligonucleotide) on different patient populations (Asian, European/Caucasian), and predicted by different classification algorithms (WV, SVM, ANN). The commonality of these results on both our data set and publicly available data sets suggests that the correlation between high ERBB2 expression and 'lowconfidence' prediction status may be an inherent feature of breast cancer in general.
A significant proportion of genes perturbed in the low-confidence samples are not known to be regulated by estrogen and lack potential EREs in their promoters
The strong correlation between high ERBB2 levels and the widespread perturbations of ER-subtype discriminating genes observed in the 'low-confidence' tumors raises the possibility that ERBB2 may functionally contribute towards this phenomenon. One possible mechanism by which this could occur is through ERBB2 signaling which has been proposed to inhibit the transcriptional activity of ER (see Discussion). Under this scenario, one might expect that a significant proportion of the genes perturbed between the 'high-confidence' (ERBB2À) and 'low-confidence' (ERBB2þ) tumors would consist of genes regulated by ER. We tested this hypothesis in two ways. First, we compared our list of significantly perturbed genes (Table 2) to SAGE expression data derived from estrogen (E2) stimulated MCF-7 cells (13) to determine if the extent of overlap between the two. Only two genes (STC2, TFF1) were found in common between the SAGE data and the 'perturbed' gene list, and one (TFF1) was regulated in the opposite manner from that expected, exhibiting higher expression in the ERBB2þ samples. This result, within the limits of the cell line assay, suggests that many of the 'perturbed' genes in the 'low-confidence' tumors may not be directly regulated by estrogen. All patients in the Rosetta data set were node-negative. d Tumor size in the Stanford data set was defined using the CAT system.
putative EREs in the promoter regions of the perturbed genes (14) . The prediction accuracy of DEREF has been validated in a number of in vivo examples-it detects ERE patterns 2.8Â more frequently in the promoter regions of estrogen responsive versus non-responsive genes in a microarray experiment, and 5.4Â more frequently in the promoters of genes belonging to the estrogen-induced SAGE dataset versus genes whose expression is negatively correlated to ER in breast cancers (see Supplementary Material for a more extensive characterization of DEREF). Of the top 50 perturbed genes in the ERþ tumors (Table 2) , the transcriptional start sites of 35 could be accurately determined and thus were subsequently analyzed by DEREF. Of this 35, EREs were detected with high-confidence in only 12 promoters (total frequency 34%) ( Table 2) . Conversely, of the top 50 perturbed genes in the ERÀ tumors, 33 were analyzed by DEREF and high-confidence EREs were detected in only three (total frequency 9%; Table 2 ). Thus, EREs were detected in the promoters of perturbed genes in ERþ tumors at 3.7Â higher frequency than in the ERÀ tumors. This difference was significant by a chi-square analysis (P ¼ 0.012), suggesting that ERBB2 may affect transcription in ERþ and ERÀ tumors via distinct mechanisms (see Discussion). Regardless, EREs were not detected as overrepresented in the perturbed genes in both subtypes (ERþ and ERÀ), suggesting that these genes may not be direct transcriptional targets of ER. These genes may represent either indirect targets of ER, or may be transcriptionally regulated via ER-independent mechanisms.
DISCUSSION
There has been an intense interest in the use of gene expression profiles for biological classification, particularly in the fields of oncology and medicine. Proposed advantages of the profiling approach include the following-first, expression profiles can potentially define clinically relevant subtypes of cancer that have previously eluded more conventional approaches such as light-microscopy and IHC (15, 16) . Second, in contrast to single molecular markers, the ability to simultaneously monitor multiple genes can often provide a useful insight into the activity state of clinically significant cellular and tumorigenic pathways. Third, depending on the scoring pathologist, results from IHC may sometimes be misleading due to the presence of isolated aberrant regions-such a situation may occur when a tumor is designated ERþ due to a small area of the tumor exhibiting intense ER staining, while the remainder/majority of the tumor remains devoid of such staining. In contrast, because expression profiles are usually derived from the bulk of the tumor, they may better represent the overall collective biology of the composite tumor. Despite this potential, a number of issues have to be resolved before the use of gene expression data for clinical diagnosis can become a reality. For example, algorithms need to be implemented that, besides delivering the correct classification, can also accurately determine the confidence of the prediction. This is particularly important if the classification affects the subsequent course of treatment-if furnished with such information, the treating physician can then weigh the confidence of prediction with the potential morbidity of a specific intervention to make an informed clinical choice. The findings in this report complement and extend the previous work in this area related to the classification of breast tumors by ER subtype. In general, these studies have shown that, while gene expression data can be successfully used to classify the ER subtype of most tumors, there invariably exists a certain population of tumors that exhibit a low-confidence of prediction and thus cannot be accurately classified (3, 4) . Since these prior studies did not extensively investigate these 'lowconfidence' samples, we performed an in-depth analysis of these 'low-confidence' tumors and made a number of findings. We found that, in comparison with patients with 'highconfidence' tumors, patients with 'low-confidence' tumors exhibited a significantly worse overall survival and shorter time to distant metastasis. The 'high-' versus 'low-confidence' classification, arrived at by computational analysis of gene expression profiles, also served to separate ERþ tumors into groups exhibiting distinct clinical behaviors (Fig. 2) . Notably, the association of the 'low-confidence' category with adverse outcome was observed using data from two independent studies (Stanford and Rosetta), supporting the hypothesis that the 'low' and 'high-confidence' tumors are indeed clinically distinct. Since the discernment of such subgroups is currently not possible using conventional immuno-histopathological techniques, these results also demonstrate how the classification of a breast tumor's ER status by expression profiling and computational analysis can be medically useful.
We also made the unanticipated finding that the 'lowconfidence' state is significantly associated with elevated expression of the ERBB2 receptor. We emphasize that the connection between ERBB2 and 'low-confidence' predictions remains an association, and that at this point we have no evidence (from our own data) that ERBB2 is functionally responsible for causing the 'low-confidence' state. Nevertheless, given that ER and ERBB2 are currently the two most clinically relevant molecular biomarkers in breast cancer, it is tempting to speculate that these results suggest that there may exist substantial cross-talk between these two signaling pathways in breast cancer, a possibility that has also been proposed by others (7) . Interestingly, in a separate analysis, we have also found that there is a significant negative association between ERþ status and ERBB2 expression for our in-house and the Stanford data set, but not for the other two datasets (Supplementary Material). We also note that the association between ERBB2þ and 'low-confidence' prediction, although highly significant, is not perfect, as a few ERBB2þ tumors were also found to exhibit 'high-confidence' predictions, while not all 'low-confidence' tumors are ERBB2þ. Thus, it is unlikely the 'low-confidence' population of breast tumors could have been discerned by conventional histopathological techniques used to detect ERBB2 such as IHC and FISH. Instead, we speculate that, for tumors designated ERBB2þ by routine histopathology, further examination of these tumors for the presence of such characteristic 'expression perturbations' may be a promising method to distinguish between tumors that are likely to be more clinically aggressive versus those that will progress along a comparatively more indolent course. Exploring this possibility will be an important task for future research.
Clinically, elevated ERBB2 expression in ERþ breast tumors has long been associated with decreased sensitivity to antihormonal therapies, and a recent population-based study, using more conventional analytical methods, has also found that ERBB2 is epistatic to ER status for disease prognostication (17) . A number of experimental papers have also been reported addressing possible mechanisms by which ERBB2 activity might cause this effect. In general, the most popular model has been one in which elevated ERBB2 signaling causes ER to exhibit diminished transcriptional activity, either through transcriptional down-regulation of the ER gene (18) , posttranslational modifications of ER (e.g. phosphorylation) (19) , or via induction of ER-binding corepressors such as MTA1 (20) . If the effects of ERBB2 were mediated primarily through effects on ER transcriptional activity, then one might expect that a substantial number of the genes whose transcription is significantly perturbed in the ERBB2þ 'low-confidence' samples should correspond to genes which are direct targets of ER. We found, however, that a significant proportion of the genes that were significantly perturbed in both ERþ and ERÀ tumors have not been previously identified as estrogen-induced genes, and these genes also appear to lack potential EREs in their promoters. This is particularly the case in the ERÀ tumors, in which only 9% of the significantly perturbed genes were found to contain high-confidence putative EREs in their promoters. Although we cannot rule out the possibility that these perturbed genes may be indirect targets of ER or may be activated by ER via non-ERE mechanisms, these findings raise the possibility that ERBB2 activity may regulate a significant fraction of genes in breast tumors in an ER-independent fashion. There are numerous avenues by which this could occur. For example, ERBB2 might regulate other transcription factors besides ER through activation of the RAS/MAPK or PI3/Akt pathways (19) . Alternatively, ERBB2 activity may result in the induction of chromatin remodeling factors such as MTA1 that may cause more pleiotropic effects (20) . Our findings suggest that it may be important to perform further research along these other lines as well, in order to fully understand the factors that contribute towards the 'lowconfidence' subtype of breast tumors.
MATERIALS AND METHODS

Breast tissue samples and patient data
Breast tissue samples and clinical data were obtained from the Tissue Repository in the institution National Cancer Center of Singapore, after appropriate approvals had been obtained from the institution's Repository and Ethics Committees. Samples were grossly dissected in the operating theater immediately after surgical excision, and flash-frozen in liquid N2. Table S1 in the Supplementary Material.
Sample preparation and microarray hybridization
RNA was extracted from tissues using Trizol reagent and processed for Affymetrix Genechip hybridizations using U133A Genechips according to the manufacturer's instructions.
Data preprocessing
Raw chip scans were quality controlled using the GeneData Refiner program and deposited into a central data storage facility. The expression data was pre-processed by removing genes whose expression was absent throughout all samples (i.e. 'A' calls), subjecting the remaining genes to a log2 transformation, and mediate-centering by samples.
Prediction of ER status
Two classification algorithms, WV (21) and SVMs (22) , were used to classify breast tumors according to ER subtype. Classification accuracy is defined as the number of correctly classified samples divided by the total number of samples. For the WV analyses, classification accuracy was determined using a gene set of the top 50 discriminating genes for ER status, while the SVM-based binary classifier utilized all genes.
Weighted voting. The weighted voting algorithm utilizes a signal-to-noise (S2N) metric to perform binary classifications. Each gene belonging to a predictor set is assigned a 'vote', expressed as the weighted difference between the gene expression level in the sample to be classified and the average class mean expression level. Weighting is determined using the correlation metric Support vector machine. Support vector machines are classification algorithms which define a discrimination surface in the utilized feature (gene) space that attempts to maximally separate classes of training data (22) . An unknown test sample's position relative to the discrimination surface determines its class. Distances are usually calculated in the n-dimensional gene space, corresponding to the total number of gene expression values considered. We used SVM-FU (available at www.ai.mit.edu/projects/cbcl/) with the linear kernel to implement the SVM analysis. The confidence of each SVM prediction is based on the distance of a test sample from the discrimination surface, as previously described (23) .
Identification of low-confidence tumors
Owing to the clinical importance of achieving good prediction confidence, we conservatively chose a series of high confidence thresholds to minimize potential false positive classifications. A tumor sample was assigned to the 'low-confidence' category if its PS from WV was less than this threshold. For each of the different data sets, the threshold selected was derived from the leave-one-out cross validation (LOOCV) results ( Fig. 1 and Supplementary Material) at points where the ERþ and ERÀ tumors demonstrated qualitatively reduced prediction strengths compared with the majority of tumors. For our in-house data set, the threshold was determined from the training set only. This analysis led to thresholds of 0.4, 0.4 and 0.7 for our in-house, Stanford and Rosetta data sets respectively, corresponding to 'low-confidence' proportions of 16.7, 18.9 and 15.4% of the total number of tumors. Similar results were obtained for all data sets when the threshold cutoffs were varied by AE 10% (Supplementary Material).
Selection of differentially expressed genes and determination of expression perturbations
SAM is a statistical methodology developed to identify genes that are differentially expressed between separate groups (11) . Genes are ranked are according to their statistical likelihood of being regulated. The ranking metric is the S2N ratio, which is similar to WV. Thus, genes identified as being highly regulated by SAM will also contribute highly towards the WV discriminator. The SAM algorithm also performs a permutation analysis of the expression data to estimate the number of genes identified as being 'differentially regulated' by random chance (i.e. false positives). This number is the 'false discovery rate'. Depending upon the desired stringency, different reports have used FDRs ranging from <5 to 33% (24, 25) . Student's t-test was used to compare levels of expression in the SAM-133 gene set between 'high-' and 'low-confidence' groups. A gene was classified as exhibiting significant 'perturbed expression' if its P-value was less than 0.05.
